William Thomas O'COnnor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William Thomas O'COnnor has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Kjell Fuxe
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
25 shared publications U. Ungerstedt
23 shared publications- Sergio Tanganelli
University of Ferrara
21 shared publications - Luca Ferraro
Department of Life Sciences and Biotechnology (SVEB), University of Ferrara, Ferrara, Italy
18 shared publications Urban Ungerstedt
13 shared publications- Tiziana Antonelli
University of Ferrara
12 shared publications
Latest Publications
- Open Access
- 5 March 2024
- Published by SAGE Publications in Healthcare Management Forum
- Vol. 37 (4) , 290-295
Charting the future of patient care: A strategic leadership guide to harnessing the potential of artificial intelligence
Artificial Intelligence (AI) applications have the potential to revolutionize conventional healthcare practices, creating a more efficient and patient-centred approach with improved outcomes. This guide discuses eighteen AI-based applications in clinical decision-making, precision medicine, operational efficiency, and predictive analytics, including a real-world example of AI’s role in public health during the early stages of the COVID-19 pandemic. Additionally, we address ethical questions, transparency, data privacy, bias, consent, accountability, and liability, and the strategic measures that must be taken to align AI with ethical principles, legal frameworks, legacy information technology systems, and employee skills and knowledge. We emphasize the importance of informed and strategic approaches to harness AI’s potential and manage its challenges. Moreover, this guide underscores the importance of evaluating and integrating new skills and competencies to navigate and use AI-based technologies in healthcare management, such as technological literacy, long-term strategic vision, change management skills, ethical decision-making, and alignment with patient needs.
- 5 March 2024
- Published by SAGE Publications in Healthcare Management Forum
- Vol. 37 (4) , 290-295
Open AccessCharting the future of patient care: A strategic leadership guide to harnessing the potential of artificial intelligence
Artificial Intelligence (AI) applications have the potential to revolutionize conventional healthcare practices, creating a more efficient and patient-centred approach with improved outcomes. This guide discuses eighteen AI-based applications in clinical decision-making, precision medicine, operational efficiency, and predictive analytics, including a real-world example of AI’s role in public health during the early stages of the COVID-19 pandemic. Additionally, we address ethical questions, transparency, data privacy, bias, consent, accountability, and liability, and the strategic measures that must be taken to align AI with ethical principles, legal frameworks, legacy information technology systems, and employee skills and knowledge. We emphasize the importance of informed and strategic approaches to harness AI’s potential and manage its challenges. Moreover, this guide underscores the importance of evaluating and integrating new skills and competencies to navigate and use AI-based technologies in healthcare management, such as technological literacy, long-term strategic vision, change management skills, ethical decision-making, and alignment with patient needs.
- Open Access
- 17 October 2022
- Published by Portico in BMJ Open Science
- Vol. 6 (1) , e100276
Protocol for a systematic review of the validity of animal models of polydipsia with a basis in schizophrenia aetiology
Objective Primary polydipsia most commonly affects those with schizophrenia. The pathophysiology of this occurrence is not established. The aim of this systematic review is to critically assess the internal and external validity of the preclinical animal models available. Search strategy PubMed and Embase will be searched systematically to identify all relevant animal studies that describe polydipsia induction with a basis in schizophrenia aetiology. The SYRCLE (SYstematic Review Center for Laboratory animal Experimentation) search filters to identify all animal studies in both databases will be used. All studies published up to the date of the search will be considered. Screening and annotation Two independent reviewers will screen the retrieved studies for eligibility based on (1) title and abstract and (2) full text. Disagreements between researchers will be resolved by discussion and referral back to the predefined eligibility criteria with involvement of a third researcher if required.
- 17 October 2022
- Published by Portico in BMJ Open Science
- Vol. 6 (1) , e100276
Open AccessProtocol for a systematic review of the validity of animal models of polydipsia with a basis in schizophrenia aetiology
Objective Primary polydipsia most commonly affects those with schizophrenia. The pathophysiology of this occurrence is not established. The aim of this systematic review is to critically assess the internal and external validity of the preclinical animal models available. Search strategy PubMed and Embase will be searched systematically to identify all relevant animal studies that describe polydipsia induction with a basis in schizophrenia aetiology. The SYRCLE (SYstematic Review Center for Laboratory animal Experimentation) search filters to identify all animal studies in both databases will be used. All studies published up to the date of the search will be considered. Screening and annotation Two independent reviewers will screen the retrieved studies for eligibility based on (1) title and abstract and (2) full text. Disagreements between researchers will be resolved by discussion and referral back to the predefined eligibility criteria with involvement of a third researcher if required.
- 1 June 2015
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 150, 47-80
Clozapine and GABA transmission in schizophrenia disease models
- 1 June 2015
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 150, 47-80
Clozapine and GABA transmission in schizophrenia disease models
- 31 August 2014
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 15 (7) , 681-690
Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson’s Disease and Schizophrenia
The tridecapeptide neurotensin (NT) acts as neurotransmitter in the central nervous system and in the periphery. NT and NT receptors are largely localized in dopamine (DA)-enriched regions of the mammalian brain. Accordingly, numerous studies indicate the presence of close functional interactions between DA neurons and the peptide. Among others mechanisms, it has been suggested that NT could modulate nigrostriatal, mesolimbic and meso-cortical DA transmission through an antagonistic receptor-receptor interaction between the NT receptor subtype 1 (NTS1) and the dopamine D2 receptor (D2R). In particular, it was originally demonstrated that the peptide reduces the D2R agonist affinity in striatal sections and in striatal membrane preparations. These effects could be a consequence of the direct allosteric NTS1/D2 receptor interactions leading to a decrease in the DA agonist affinity at the D2 receptor. Several neurochemical, biochemical and co-immunoprecipitation data have successively reinforced the indication of the presence of direct NTS1-D2 receptor interactions in the mammalian brain. The present mini-review attempts to provide a summary of current knowledge, mainly emerging from our microdialysis studies, supporting the presence of a NTS1/D2 receptor heteromer in the brain. The pre and post-synaptic mechanisms underlying the involvement of this heteromer in the striatopallidal GABA and mesocorticolimbic DA neurotransmission are discussed especially for their relevance in Parkinson’s disease and schizophrenia, respectively.
- 31 August 2014
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 15 (7) , 681-690
Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson’s Disease and Schizophrenia
The tridecapeptide neurotensin (NT) acts as neurotransmitter in the central nervous system and in the periphery. NT and NT receptors are largely localized in dopamine (DA)-enriched regions of the mammalian brain. Accordingly, numerous studies indicate the presence of close functional interactions between DA neurons and the peptide. Among others mechanisms, it has been suggested that NT could modulate nigrostriatal, mesolimbic and meso-cortical DA transmission through an antagonistic receptor-receptor interaction between the NT receptor subtype 1 (NTS1) and the dopamine D2 receptor (D2R). In particular, it was originally demonstrated that the peptide reduces the D2R agonist affinity in striatal sections and in striatal membrane preparations. These effects could be a consequence of the direct allosteric NTS1/D2 receptor interactions leading to a decrease in the DA agonist affinity at the D2 receptor. Several neurochemical, biochemical and co-immunoprecipitation data have successively reinforced the indication of the presence of direct NTS1-D2 receptor interactions in the mammalian brain. The present mini-review attempts to provide a summary of current knowledge, mainly emerging from our microdialysis studies, supporting the presence of a NTS1/D2 receptor heteromer in the brain. The pre and post-synaptic mechanisms underlying the involvement of this heteromer in the striatopallidal GABA and mesocorticolimbic DA neurotransmission are discussed especially for their relevance in Parkinson’s disease and schizophrenia, respectively.
- 1 April 2014
- Published by Elsevier in International Journal of Greenhouse Gas Control
- Vol. 23, 119-134
Geochemical alteration of simulated wellbores of CO2 injection sites within the Illinois and Pasco Basins
- 1 April 2014
- Published by Elsevier in International Journal of Greenhouse Gas Control
- Vol. 23, 119-134
Geochemical alteration of simulated wellbores of CO2 injection sites within the Illinois and Pasco Basins
GET73 increases rat extracellular hippocampal CA1 GABA levels through a possible involvement of local mGlu5 receptor
N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide (GET73) is a newly synthesized compound displaying anti-alcohol and anxiolytic properties. In light of the importance of the hippocampal CA1 subregion in alcohol addiction and anxiety-like behaviors—this in vivo microdialysis study characterized the effect of GET73 on extracellular GABA levels in the hippocampal CA1 region of the freely moving rat—including a possible role for mGlu5 receptor in mediating this effect. Both intraperitoneal administration (2–10 mg/kg) and local intra-hippocampal CA1 perfusion with GET73 (50–1000 nM) were associated with a transient, step-wise increase in dialysate hippocampal CA1 GABA levels. The GET73 (10 mg/kg)-induced increase in GABA levels was not affected by intra-CA1 perfusion with either the GABA reuptake inhibitor SKF89976A (0.5 mM) or by local GABAA (bicuculline; 1μM) and GABAB (CGP35348; 500 μM) receptor antagonists. On the contrary, the GET73-induced increase in GABA levels was partially counteracted by the intra-CA1 perfusion with the mGlu5 receptor negative allosteric modulator MPEP (300 µM). Interestingly, GET73 at the lowest (2 mg/kg) dose tested, by itself ineffective, fully counteracted the increase in GABA levels induced by the mGlu5 receptor agonist CHPG (1000 µM). Taken together, these findings suggest that the GET73-induced increase in hippocampal CA1 GABA levels operates independently of local GABA reuptake and/or GABAA or GABAB receptors. Furthermore, the present data lead to hypothesize a possible interaction between GET73 and mGluR5-mediated regulation of hippocampal CA1 GABA transmission, an effect which may be relevant to the ability of GET73 to reduce alcohol intake in an alcohol-preferring rat strain. Synapse 67:678–691, 2013.
GET73 increases rat extracellular hippocampal CA1 GABA levels through a possible involvement of local mGlu5 receptor
N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide (GET73) is a newly synthesized compound displaying anti-alcohol and anxiolytic properties. In light of the importance of the hippocampal CA1 subregion in alcohol addiction and anxiety-like behaviors—this in vivo microdialysis study characterized the effect of GET73 on extracellular GABA levels in the hippocampal CA1 region of the freely moving rat—including a possible role for mGlu5 receptor in mediating this effect. Both intraperitoneal administration (2–10 mg/kg) and local intra-hippocampal CA1 perfusion with GET73 (50–1000 nM) were associated with a transient, step-wise increase in dialysate hippocampal CA1 GABA levels. The GET73 (10 mg/kg)-induced increase in GABA levels was not affected by intra-CA1 perfusion with either the GABA reuptake inhibitor SKF89976A (0.5 mM) or by local GABAA (bicuculline; 1μM) and GABAB (CGP35348; 500 μM) receptor antagonists. On the contrary, the GET73-induced increase in GABA levels was partially counteracted by the intra-CA1 perfusion with the mGlu5 receptor negative allosteric modulator MPEP (300 µM). Interestingly, GET73 at the lowest (2 mg/kg) dose tested, by itself ineffective, fully counteracted the increase in GABA levels induced by the mGlu5 receptor agonist CHPG (1000 µM). Taken together, these findings suggest that the GET73-induced increase in hippocampal CA1 GABA levels operates independently of local GABA reuptake and/or GABAA or GABAB receptors. Furthermore, the present data lead to hypothesize a possible interaction between GET73 and mGluR5-mediated regulation of hippocampal CA1 GABA transmission, an effect which may be relevant to the ability of GET73 to reduce alcohol intake in an alcohol-preferring rat strain. Synapse 67:678–691, 2013.
- 1 August 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 36-40
What can the brain science of learning teach us about cybernetics?
The study of perception, learning, memory and recall are converging to unite the emerging brain science of learning with the field of cybernetics and to bridge the gap between the mechanistic models of brain function with the knowledge of us as being a lot more than just our brains. Human beings cannot be defined by their physical body or brain alone - just as electricity cannot be defined by the nerves through which it travels. The human brain is in fact, a system in constant flux. This distinction between the brain and the mind - that man is not a machine but has and uses a machine - the brain - is critical in understanding how we as humans learn and evolve. Recent research shows that different circuits are called upon in the brain for different activities such as math, music and reading. In addition, learning and practicing particular skills can cause corresponding areas in the brain to grow or change by adding a tiny fraction of the brain's neural circuitry and eliminating old ones. This finding is of particular interest to cybernetics which questions as to how psychological/cognitive functions are produced by brain circuits. This paper contributes to this dialogue by summarizing what we already know about the learning process in the brain and suggests how systems of communication and control operate in the brain during deep learning as for example during problem based learning.
- 1 August 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 36-40
What can the brain science of learning teach us about cybernetics?
The study of perception, learning, memory and recall are converging to unite the emerging brain science of learning with the field of cybernetics and to bridge the gap between the mechanistic models of brain function with the knowledge of us as being a lot more than just our brains. Human beings cannot be defined by their physical body or brain alone - just as electricity cannot be defined by the nerves through which it travels. The human brain is in fact, a system in constant flux. This distinction between the brain and the mind - that man is not a machine but has and uses a machine - the brain - is critical in understanding how we as humans learn and evolve. Recent research shows that different circuits are called upon in the brain for different activities such as math, music and reading. In addition, learning and practicing particular skills can cause corresponding areas in the brain to grow or change by adding a tiny fraction of the brain's neural circuitry and eliminating old ones. This finding is of particular interest to cybernetics which questions as to how psychological/cognitive functions are produced by brain circuits. This paper contributes to this dialogue by summarizing what we already know about the learning process in the brain and suggests how systems of communication and control operate in the brain during deep learning as for example during problem based learning.
- 1 August 2012
- Published by Elsevier in Journal of Power Sources
- Vol. 211, 192-201
Partitioning of coal contaminants in the components of liquid tin anode solid oxide fuel cells
- 1 August 2012
- Published by Elsevier in Journal of Power Sources
- Vol. 211, 192-201
Partitioning of coal contaminants in the components of liquid tin anode solid oxide fuel cells
- 1 May 2011
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 130 (2) , 106-113
Animal models of traumatic brain injury: A critical evaluation
- 1 May 2011
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 130 (2) , 106-113
Animal models of traumatic brain injury: A critical evaluation
- 10 February 2011
- Published by SPIE-Intl Soc Optical Eng
- Vol. 7898, 78980V
Optical coherence tomography: imaging architect for dermal microdialysis in psoriasis
Optical coherence tomography (OCT) has been used as part of a ground breaking translational study to shed some light on one of the worlds most prevalent autoimmune diseases; psoriasis. The work successfully integrates the fields of optical imaging, biochemistry and dermatology in conducting a dermal microdialysis (DMD) trial for quantitative histamine assessment amongst a group of psoriasis sufferers. The DMD process involves temporary insertion of microscopic hollow tubes into a layer of skin to measure the levels of histamine and other important biological molecules in psoriasis. For comparison purposes, DMD catheters were implanted into healthy, peri-lesional and lesional skin regions. The catheters' entry and exit points and their precise locations in the epidermal layer of the skin were confirmed using OCT thus obtaining high resolution, wide-field images of the affected skin as well as catheter placement whilst local microdialysis enabled a tissue chemistry profile to be obtained from these three skin regions including histamine, a local immune system activator known to contribute towards itch and inflammation. Together these tools offer a synergistic approach in the clinical assessment of the disease. In addition, OCT delivered a non-invasive and rapid method for analyzing the affected skin architecture.
- 10 February 2011
- Published by SPIE-Intl Soc Optical Eng
- Vol. 7898, 78980V
Optical coherence tomography: imaging architect for dermal microdialysis in psoriasis
Optical coherence tomography (OCT) has been used as part of a ground breaking translational study to shed some light on one of the worlds most prevalent autoimmune diseases; psoriasis. The work successfully integrates the fields of optical imaging, biochemistry and dermatology in conducting a dermal microdialysis (DMD) trial for quantitative histamine assessment amongst a group of psoriasis sufferers. The DMD process involves temporary insertion of microscopic hollow tubes into a layer of skin to measure the levels of histamine and other important biological molecules in psoriasis. For comparison purposes, DMD catheters were implanted into healthy, peri-lesional and lesional skin regions. The catheters' entry and exit points and their precise locations in the epidermal layer of the skin were confirmed using OCT thus obtaining high resolution, wide-field images of the affected skin as well as catheter placement whilst local microdialysis enabled a tissue chemistry profile to be obtained from these three skin regions including histamine, a local immune system activator known to contribute towards itch and inflammation. Together these tools offer a synergistic approach in the clinical assessment of the disease. In addition, OCT delivered a non-invasive and rapid method for analyzing the affected skin architecture.